Jade Biosciences, Inc. (JBIO) Stock Analysis & Investment Frameworks
Jade Biosciences, Inc. (JBIO) stock analysis on Invetso. Review Jade Biosciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Jade Biosciences, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Jade Biosciences, Inc. Key Financial Metrics
- Market Cap: $962.23M
- Revenue: $N/A
- ROE: -49.11%
- ROIC: -37.39%
- Dividend Yield: N/A
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.